"The U.S. Food and Drug Administration today approved the MemoryShape Breast Implant to increase breast size (augmentation) for use in women at least 22 years old and to rebuild breast tissue (reconstruction) in women of any age. The MemoryShape B"...
PAREMYD® (hydroxyamphetamine hydrobromide, tropicamide) Solution is indicated for mydriasis in routine diagnostic procedures and in conditions where short-term pupil dilation is desired. PAREMYD® (hydroxyamphetamine hydrobromide, tropicamide) provides clinically significant mydriasis with partial cycloplegia.
DOSAGE AND ADMINISTRATION
One to two drops in the conjunctival sac. The onset of action with PAREMYD® (hydroxyamphetamine hydrobromide, tropicamide) Solution occurs within 15 minutes followed by maximum effect within 60 minutes. Clinically significant dilation, inhibition of pupillary light response, and partial cycloplegia last 3 hours. Mydriasis will reverse spontaneously with time, typically in 6 to 8 hours. However, in some cases, complete recovery may take up to 24 hours.
PAREMYD® (hydroxyamphetamine hydrobromide, tropicamide) (hydroxyamphetamine hydrobromide/tropicamide ophthalmic solution) 1%/0.25% as a 15 mL solution in a 15 mL opaque white, low density polyethylene bottle with a natural low density polyethylene dropper tip and a red polypropylene cap. 15 mL - NDC 17478-704-12
Note: Protect from light. Store between 15° C to 25° C (59° F to 77° F).
Manufactured by: Akorn Buffalo Grove, IL 60089. For product enquiry call: 800-932-5676 or fax 800-943-3694 • www.akorn.com
Last reviewed on RxList: 2/20/2009
This monograph has been modified to include the generic and brand name in many instances.
Additional Paremyd Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.